Cargando…

Glycemic status and risks of thromboembolism and major bleeding in patients with atrial fibrillation

BACKGROUND: Studies specifically examining the association between glycated hemoglobin A1c (HbA1c) levels and ischemic stroke/systemic thromboembolism (IS/SE) risk in atrial fibrillation (AF) patients are limited. Here, we investigated the association between HbA1c levels and the risk of IS/SE, as w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Yi-Hsin, Chuang, Chi, Chan, Cze-Ci, Lee, Hsin-Fu, Huang, Ya-Chi, Huang, Yu-Tung, Chang, Shang-Hung, Wang, Chun-Li, Chao, Tze-Fan, Kuo, Chi-Tai, Yeh, Yung-Hsin, Chen, Shih-Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063754/ https://www.ncbi.nlm.nih.gov/pubmed/32156277 http://dx.doi.org/10.1186/s12933-020-01005-8

Ejemplares similares

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

The CHA(2)DS(2)-VASc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants
por: Lee, Kuang-Tso, et al.
Publicado: (2018)

Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban
por: Chao, Tze-Fan, et al.
Publicado: (2022)

Atrial fibrillation and its arrhythmogenesis associated with insulin resistance
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

Stroke and Bleeding Risk Assessment in Atrial Fibrillation: Where Are We Now?
por: Kuo, Ling, et al.
Publicado: (2021)

Association evidence of CCTTT repeat polymorphism in the iNOS promoter and the risk of atrial fibrillation in Taiwanese
por: Hsu, Lung-An, et al.
Publicado: (2017)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
por: Chang, Chia-Yu, et al.
Publicado: (2017)

Young Male Patients with Atrial Fibrillation and CHA(2)DS(2)-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study
por: Chan, Yi-Hsin, et al.
Publicado: (2016)

Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)

MMP9 Rs3918242 Polymorphism Affects Tachycardia-Induced MMP9 Expression in Cultured Atrial-Derived Myocytes but Is Not a Risk Factor for Atrial Fibrillation among the Taiwanese
por: Hsiao, Fu-Chih, et al.
Publicado: (2016)

Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants
por: Chan, Yi-Hsin, et al.
Publicado: (2020)

Aldehyde Dehydrogenase 2 Ameliorates Chronic Alcohol Consumption-Induced Atrial Fibrillation through Detoxification of 4-HNE
por: Hsu, Lung-An, et al.
Publicado: (2020)

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Ling, Ann Wan-Chin, et al.
Publicado: (2020)

The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
por: Chan, Yi-Hsin, et al.
Publicado: (2022)

Microsatellite Polymorphism in the Heme Oxygenase-1 Gene Promoter and the Risk of Atrial Fibrillation in Taiwanese
por: Hsu, Lung-An, et al.
Publicado: (2014)

Clinical outcomes of generic versus brand‐name clopidogrel for secondary prevention in patients with acute myocardial infarction: A nationwide cohort study
por: Chan, Cze Ci, et al.
Publicado: (2023)

A Novel DES L115F Mutation Identified by Whole Exome Sequencing is Associated with Inherited Cardiac Conduction Disease
por: Hsu, Lung-An, et al.
Publicado: (2019)

miR-181b targets semaphorin 3A to mediate TGF-β–induced endothelial-mesenchymal transition related to atrial fibrillation
por: Lai, Ying-Ju, et al.
Publicado: (2022)

Different Implications of Heart Failure, Ischemic Stroke, and Mortality Between Nonvalvular Atrial Fibrillation and Atrial Flutter—a View From a National Cohort Study
por: Lin, Yu‐Sheng, et al.
Publicado: (2017)

Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Lee, Hsin-Fu, et al.
Publicado: (2023)

Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study
por: Chan, Cze-Ci, et al.
Publicado: (2021)

Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—A nationwide cohort study
por: Wu, Hsin-Hsu, et al.
Publicado: (2022)

Case report: Sudden cardiorespiratory collapse in a healthy male after coronavirus disease 2019 vaccination at a vaccination center
por: Chan, Cze Ci, et al.
Publicado: (2022)

In-hospital direct costs for thromboembolism and bleeding in Chinese patients with atrial fibrillation
por: Chang, San-Shuai, et al.
Publicado: (2018)

Obesity phenotypes and their relationships with atrial fibrillation
por: Tsai, Szu-Ying, et al.
Publicado: (2021)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
por: Liao, Jo-Nan, et al.
Publicado: (2022)

Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
por: Lee, Hsin-Fu, et al.
Publicado: (2020)

Risk of Thromboembolism in Non-Valvular Atrial Fibrillation With or Without Clinical Hyperthyroidism
por: Lin, Yu-Sheng, et al.
Publicado: (2021)

Left ventricular dysfunction in atrial fibrillation and heart failure risk
por: Kuo, Jen‐Yuan, et al.
Publicado: (2020)

Gallstone associated celiac trunk thromboembolisms complicated with splenic infarction: A case report
por: Wu, Chia-Ying, et al.
Publicado: (2022)

The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2019)

Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
por: Huang, Hsin-Yi, et al.
Publicado: (2018)

Pilot study of peripheral blood chemokines as biomarkers for atrial fibrillation-related thromboembolism and bleeding in elderly patients
por: Tai, Meihui, et al.
Publicado: (2022)

Familial aggregation of myocardial infarction and coaggregation of myocardial infarction and autoimmune disease: a nationwide population-based cross-sectional study in Taiwan
por: Wang, Chun-Li, et al.
Publicado: (2019)

Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction
por: Kuo, Jen-Yuan, et al.
Publicado: (2022)

A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan
por: Wu, Lung-Sheng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g64i5d16p97g4n4nsj85j6qu0o